About Imvaria
Imvaria is a pioneering healthcare AI company that develops AI-driven digital biomarker solutions for serious diseases, primarily focusing on lung conditions. The company’s core innovation lies in generating physiologic signatures from clinical testing and imaging data, which allows for earlier and more accurate diagnoses while potentially reducing the need for invasive procedures.
For physicians, Imvaria offers FDA-authorized AI tools like Fibresolve and ScreenDx. Fibresolve is an AI diagnostic adjunct that analyzes lung CT imaging to provide a diagnostic subtype classification in suspected interstitial lung disease (ILD), specifically assisting in the pre-invasive assessment of idiopathic pulmonary fibrosis (IPF). ScreenDx is an automated background AI algorithm that analyzes CT imaging to detect interstitial lung findings compatible with ILD and flags cases for referral workflows, aiming to reduce diagnostic delays. Imvaria also has an investigational AI tool called Bronchosolve, which is designed to automate risk assessment for suspicious pulmonary nodules detected on screening CTs. The company operates a centralized, cloud-based AI Lab where clinicians, health systems, and clinical trialists can transmit de-identified cases for automated machine learning analysis, receiving diagnostic reports in minutes.
Focus Areas
Business Intelligence
| Technology | IMVARIA's AI Lab is a centralized, cloud-based digital lab that utilizes automated, machine-learning algorithm technology. It employs deep learning, convolutional neural networks, and multi-modal data fusion (imaging + labs + clinical data) for analysis. The platform is designed for Software-as-Medical-Device (SaMD) tools, offering a remote service that accepts de-identified clinical cases, runs automated ML analyses, and returns diagnostic reports. |
What Physicians Need to Know
IMVARIA's tools, Fibresolve and ScreenDx, are designed to be adjunctive to current standard-of-care workflows, providing supplementary information to qualified clinicians. They aim to simplify the integration of AI into practice by offering a centralized, cloud-based AI Lab where clinicians can transmit de-identified cases (imaging and lab data) and receive reports with AI analysis results in minutes, without requiring complex software installations or workflow changes. This can lead to earlier and more accurate diagnoses, potentially preventing unnecessary treatments and improving patient outcomes in complex lung diseases.
IMVARIA operates a centralized, cloud-based 'AI Lab' that functions similarly to a specialty CLIA lab, processing data rather than physical samples. This model emphasizes ease of use with 'no integration, no software' required for clinicians; they simply refer cases and receive results. IMVARIA has also formed strategic partnerships, such as with Viz.ai, to expand their pulmonary portfolio and integrate new AI capabilities for assessing ILD. They also offer their AI Lab services to other companies, such as providing InVision's Precision Cardiac Amyloid AI for cardiac amyloidosis detection.
What the Web Says
Imvaria is a healthcare technology company specializing in AI-driven digital biomarker solutions, with a primary product called ScreenDx. ScreenDx is an FDA-cleared AI-powered algorithm designed to automatically assess CT scans for interstitial lung findings compatible with Interstitial Lung Disease (ILD). The company aims to enhance referral pathways and reduce diagnostic delays for ILD patients by integrating AI into clinical testing and imaging. While there is significant information available about their product's capabilities and FDA clearance, comprehensive independent product and employer reviews on platforms like G2, Glassdoor, Capterra, and Reddit are limited or not directly available for "Imvaria" or "ScreenDx" at this time.
Overall: PositiveStrengths
- ScreenDx is a first-of-its-kind, FDA-cleared AI technology for assessing CT scans for interstitial lung findings compatible with ILD.
- The ScreenDx algorithm has demonstrated high performance in identifying incidental cases of pulmonary fibrosis across various CT manufacturers and slice thicknesses, suggesting generalizability.
- ScreenDx operates as a quiet, background-only technology, automatically sifting through thousands of CT scans without requiring expert user operation.
- The technology is designed to be supplementary to current standard-of-care workflows, providing adjunctive information to improve referral pathways and reduce diagnostic delays for ILD.
- Imvaria is pioneering work with clinical AI to redefine how to approach high-impact diseases more effectively.
Limitations
- Limited independent product reviews for ScreenDx were found on major review platforms like G2, Capterra, and Reddit.
- No specific employer reviews for "Imvaria" were found on Glassdoor or similar platforms.
- General concerns about AI in medical diagnostics on Reddit suggest that AI is still in development and may have a high margin of error in detecting normal anatomical differences versus concerning lesions.
- Some general reviews of AI medical diagnostic platforms mention challenges with complexity, data security, and lack of APIs for interoperability.
Based on reviews from: Business Wire, PubMed, IMVARIA (imvaria.com), MedTech Innovator, G2, Reddit
Last updated: 2026-10-17
Videos
News, demos, and interviews about Imvaria.
Videos load interactively. If none appear, search YouTube for Imvaria →
Press & Coverage
Frequently Asked Questions
Investors
Who's funded Imvaria.
Comparisons
Related Companies
A2z Radiology AI is a Boston-based medical imaging AI company that develops software for comprehensive CT interpretation, initially focusing on abdomen-pelvis CT scans. The company’s primary goal is to enhance diagnostic accuracy and efficiency in medical imaging for healthcare providers by leveraging artificial intelligence. Their flagship product, a2z-Unified-Triage, is FDA-cleared radiological computer-aided triage and notification […]
OpenAI is an American artificial intelligence (AI) company that conducts research and develops advanced AI models. While widely known for its generative AI models like ChatGPT and DALL-E, OpenAI has significantly expanded its focus into the healthcare sector. The company’s mission is to ensure that artificial general intelligence (AGI) benefits all of humanity, and this […]
Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]
Veeva Systems is a global leader in cloud-based software solutions specifically designed for the life sciences industry, including pharmaceutical and biotech companies. The company’s offerings are crucial for managing various aspects of drug development, pharmaceutical manufacturing, and commercial operations. Their platforms help clients navigate complex regulatory requirements, improve operational efficiency, and accelerate the delivery of […]
The University at Buffalo (UB) is a prominent public research university and a flagship institution of the State University of New York (SUNY) system. While UB itself is a broad academic institution, the provided URL (halsted.compbio.buffalo.edu) points to a specific area within UB focused on computational biology. This division is actively engaged in healthcare AI […]
SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]